Eli Lilly saw first-quarter profits double as sales of its weight-loss drug soared.
GLP-1 drugs have changed not just the pharmaceutical industry — although they have, briefly making Novo Nordisk Europe’s biggest company by market capitalization — but also people’s health and habits.
US obesity peaked in 2022 after decades of continuous rises; the subsequent decline coincides with the rise of the drugs.
The fast-food industry has seen falling sales and analysts suggest foodmakers may have to overhaul their offerings.
The drugs may also affect decision-making away from food: A small, recent study found that subjects with alcohol-use disorder drank less while using semaglutide, supporting anecdotal evidence from patients and doctors.
此内容由惯性聚合(RSS阅读器)自动聚合整理，仅供阅读参考。 原文来自 — 版权归原作者所有。